Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	National Committee for Technology Incorporation (CONITEC)	[Orlistat for weight loss in overweight or obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Public Health Research (PHR) programme	A two arm feasibility trial of lifestyle information and Slimming World groups to promote weight management and positive lifestyle behaviour in postnatal women from an ethnically diverse inner city population
2020	National Committee for Technology Incorporation (CONITEC)	[Sibutramine for the treatment of obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020	National Committee for Technology Incorporation (CONITEC)	[Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	NIHR Health Services and Delivery Research programme	Evaluating the use of patient experience data to improve the quality of inpatient mental health care
2020	NIHR Health Technology Assessment programme	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020	National Committee for Technology Incorporation (CONITEC)	[Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020	NIHR Health Technology Assessment programme	An extended stroke rehabilitation service for people who have had a stroke: the EXTRAS RCT
2020	NIHR Health Technology Assessment programme	Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020	National Committee for Technology Incorporation (CONITEC)	[Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020	Agency for Care Effectiveness (ACE)	Acupuncture for adults with low back pain and neck pain
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 months to < 18 years, with R117H mutation)- Benefit assessment according to §35a Social Code Book V]
2020	NIHR Public Health Research (PHR) programme	The effectiveness of promotional campaigns associated with revised UK drinking guidelines: a prospective evaluation
2020	National Committee for Technology Incorporation (CONITEC)	[Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Impact of community health worker certification on workforce and service delivery for asthma and other selected chronic diseases
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Scientific elaboration of a concept for an application-accompanying data collection and analysis for the drug onasemnogene abeparvovec in order to prepare a decision according to §35a (3b) Social Code Book V - Rapid report]
2020	National Committee for Technology Incorporation (CONITEC)	[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	NIHR Health Technology Assessment programme	Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Fall-safe assist. Portable device for falls prevention]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Naldemedine (opioid-induced constipation) - Addendum to Commission A20-45]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficiency of 3D reconstruction in maxillofacial surgery]
2020	NIHR Health Technology Assessment programme	Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lung cancer screening using low-dose computed tomography]
2020	Agency for Healthcare Research and Quality (AHRQ)	Interventions for breathlessness in patients with advanced cancer
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2020	NIHR Health Technology Assessment programme	The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: a realist review and feasibility study for a cluster randomised controlled trial
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Collagen-covered and periosteum-covered autologous chondrocyte implantation in the knee joint as well as matrix-associated autologous chondrocyte implantation in the knee joint]
2020	Agency for Healthcare Research and Quality (AHRQ)	Interventions for substance use disorders in adolescents: a systematic review
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2020	NIHR Health Technology Assessment programme	Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study
2020	NIHR Health Services and Delivery Research programme	Effects of increased distance to urgent and emergency care facilities resulting from health services reconfiguration: a systematic review
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid for amputations in diabetic foot syndrome - Rapid Report]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Labor dystocia
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Health Technology Assessment programme	CARer-ADministration of as-needed sub-cutaneous medication for breakthrough symptoms in home-based dying patients: a UK study (CARiAD)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid review: alternatives to timolol for the treatment of glaucoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Care Effectiveness (ACE)	Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Spyglass® cholangiopancreatoscopy for biliary and pancreatic diseases]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Management of colonic diverticulitis
2020	NIHR Health Services and Delivery Research programme	Factors influencing the utilisation of free-standing and alongside midwifery units in England: a mixed methods research study
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
2020	Ontario Health	Implantable devices for single-sided deafness and conductive or mixed hearing loss: a health technology assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with carotid artery disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Talazoparib (breast cancer) - Addendum to Commission A20-48]
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Leadless pacemaker for right ventricle pacing (Update 2020)
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Precice® intramedullary nail system, with external remote controller, for limb length discrepancy]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V]
2020	Haute Autorite de sante (HAS)	[New bariatric surgery techniques: identification, progress report and assessment opportunities]
2020	NIHR Health Technology Assessment programme	Adding web-based behavioural support to exercise referral schemes for inactive adults with chronic health conditions: the e-coachER RCT
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fetal neurosonography in suspected central nervous system abnormalities]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Renal replacement therapies in acute kidney failure]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Management of primary headaches in pregnancy
2020	Ontario Health	Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Intrauterine ultrasound-guided transcervical radiofrequency ablation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intravascular ultrasound in coronary artery disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2020	Center for Drug Evaluation (CDE)	The health technology assessment of bipolar TURP, bipolar TUVP (vaporization of the prostate), Green Light TM, thulium, holmium, and diode laser prostatectomy in Taiwan
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for heart transplantations in adults - Rapid Report]
2020	NIHR Health Technology Assessment programme	Two speeds of increasing milk feeds for very preterm or very low-birthweight infants: the SIFT RCT
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Summary: investigation, treatment and follow-up algorithm - lung cancer]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Parenteral infusion pump during general hospital ward]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glasdegib (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Ontario Health	Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)